Long-term follow-up of people treated with genetically modified T cells
Follows people with blood cancers for up to 15 years after CAR T cell therapy.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Key facts
- Where
- Barcelona, SpainSee the site
- Phase
- Phase 2
Where in Spain
- Hospital Vall d'HebronBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Autolus Limited
- Trial code
- NCT03628612
- Record updated
- 22 September 2026
- Original description
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.Read full original descriptionShow less
Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
Inclusion: Patients must have received an AUTO CAR T cell therapy on a clinical treatment study; Patients must have provided informed consent for long-term follow-up study prior to participation; Patients must be able to comply with the study requirements.
Exclusion: There are no specific exclusion criteria for this study.